Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/art.39814 http://scihub22266oqcxt.onion/10.1002/art.39814 C5839649!5839649 !27428710     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27428710 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Arthritis+Rheumatol 2017 ; 69 (1 ): 185-193 Nephropedia Template TP {{tp|p=27428710 |t=2017. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |pdf=|usr=}}{{27428710 }} gab.com Text Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis JO: Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27428710 #FOAvip OBJECTIVE: S100A8/A9 (calprotectin) has shown promise as a biomarker for predicting relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This study was undertaken to investigate serum S100A8/A9 level as a biomarker for predicting future relapse in a large cohort of patients with severe AAV. METHODS: Serum levels of S100A8/A9 were measured at baseline and months 1, 2, and 6 following treatment initiation in 144 patients in the Rituximab in ANCA-Associated Vasculitis trial (cyclophosphamide/azathioprine versus rituximab [RTX] for induction of remission) in whom complete remission was attained. RESULTS: Patients were divided into 4 groups: proteinase 3 (PR3)-ANCA with relapse (n?=?37), PR3-ANCA without relapse (n?=?56), myeloperoxidase (MPO)-ANCA with relapse (n?=?6), and MPO-ANCA without relapse (n?=?45). Serum S100A8/A9 level decreased in all groups during the first 6 months of treatment. The percentage reduction from baseline to month 2 was significantly different between patients who experienced a relapse and those who did not in the PR3-ANCA group (P?=?0.046). A significantly higher risk of relapse was associated with an increase in S100A8/A9 level between baseline and month 2 (P?=?0.0043) and baseline and month 6 (P?=?0.0029). Subgroup analysis demonstrated that patients treated with RTX who had increased levels of S100A8/A9 were at greatest risk of future relapse (P?=?0.028). CONCLUSION: An increase in serum S100A8/A9 level by month 2 or 6 compared to baseline identifies a subgroup of PR3-ANCA patients treated with RTX who are at higher risk of relapse by 18 months. Since RTX is increasingly used for remission induction in PR3-ANCA-positive patients experiencing a relapse, S100A8/A9 level may assist in identifying those patients requiring more intensive or prolonged treatment. Twit Text FOAVip Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis ????Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=27428710 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27428710 #FOAvip English Wikipedia <ref>{{Cite pmid|27428710 }}</ref> Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis #MMPMID27428710 Pepper RJ ; Draibe JB ; Caplin B ; Fervenza FC ; Hoffman GS ; Kallenberg CG ; Langford CA ; Monach PA ; Seo P ; Spiera R ; William St Clair E ; Tchao NK ; Stone JH ; Specks U ; Merkel PA ; Salama AD Arthritis Rheumatol 2017[Jan]; 69 (1 ): 185-193 PMID27428710 show ga OBJECTIVE: S100A8/A9 (calprotectin) has shown promise as a biomarker for predicting relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This study was undertaken to investigate serum S100A8/A9 level as a biomarker for predicting future relapse in a large cohort of patients with severe AAV. METHODS: Serum levels of S100A8/A9 were measured at baseline and months 1, 2, and 6 following treatment initiation in 144 patients in the Rituximab in ANCA-Associated Vasculitis trial (cyclophosphamide/azathioprine versus rituximab [RTX] for induction of remission) in whom complete remission was attained. RESULTS: Patients were divided into 4 groups: proteinase 3 (PR3)-ANCA with relapse (n?=?37), PR3-ANCA without relapse (n?=?56), myeloperoxidase (MPO)-ANCA with relapse (n?=?6), and MPO-ANCA without relapse (n?=?45). Serum S100A8/A9 level decreased in all groups during the first 6 months of treatment. The percentage reduction from baseline to month 2 was significantly different between patients who experienced a relapse and those who did not in the PR3-ANCA group (P?=?0.046). A significantly higher risk of relapse was associated with an increase in S100A8/A9 level between baseline and month 2 (P?=?0.0043) and baseline and month 6 (P?=?0.0029). Subgroup analysis demonstrated that patients treated with RTX who had increased levels of S100A8/A9 were at greatest risk of future relapse (P?=?0.028). CONCLUSION: An increase in serum S100A8/A9 level by month 2 or 6 compared to baseline identifies a subgroup of PR3-ANCA patients treated with RTX who are at higher risk of relapse by 18 months. Since RTX is increasingly used for remission induction in PR3-ANCA-positive patients experiencing a relapse, S100A8/A9 level may assist in identifying those patients requiring more intensive or prolonged treatment. |Adolescent [MESH] |Adult [MESH] |Aged [MESH] |Aged, 80 and over [MESH] |Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*blood/*drug therapy [MESH] |Antibodies, Antineutrophil Cytoplasmic [MESH] |Biomarkers/blood [MESH] |Double-Blind Method [MESH] |Female [MESH] |Humans [MESH] |Immunologic Factors/*therapeutic use [MESH] |Leukocyte L1 Antigen Complex/*blood [MESH] |Male [MESH] |Middle Aged [MESH] |Myeloblastin [MESH] |Predictive Value of Tests [MESH] |Recurrence [MESH] |Rituximab/*therapeutic use [MESH] |Severity of Illness Index [MESH]Association of Serum Calprotectin (S100A8/A9) Level With Disease Relap(epmc).pdf DeepDyve Pubget Overpricing